Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ARCT
ARCT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARCT News
Arcturus to Present mRNA Technologies at J.P. Morgan Healthcare Conference
Jan 08 2026
Businesswire
Arcturus Announces Launch of 12-Week Cystic Fibrosis Study in 2026, Facing Cost Management and KOSTAIVE BLA Delays
Nov 10 2025
SeekingAlpha
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
Nov 10 2025
PRnewswire
Cathie Wood Reduces Holdings in AMD and Other U.S. Tech Stocks, Increases Investment in Baidu and Biotech Sectors
Oct 25 2025
TipRanks
Molina Healthcare Analyst Adopts Bearish Stance; Check Out the Top 5 Downgrades for Friday
Oct 24 2025
Benzinga
Citi Downgrades Arcturus to Neutral Following mRNA Candidate Data Release
Oct 24 2025
SeekingAlpha
Cathie Wood Makes Major Investments in Alibaba, Baidu, and Arcturus While Reducing Holdings in AMD, SoFi, and Shopify
Oct 24 2025
TipRanks
Investor Notice: Pomerantz Law Firm Probes Allegations for Arcturus Therapeutics Holdings Inc. Investors - ARCT
Oct 24 2025
Globenewswire
Cathie Wood Invests Heavily in This Undervalued Biotech Stock
Oct 23 2025
TipRanks
Citigroup Lowers Arcturus Therapeutics Rating to Neutral and Reduces Price Target to $12
Oct 23 2025
Benzinga
Analyst Observes Mixed Results as Arcturus' Investigational Inhaled Therapy Shows No Significant Lung Function Improvement
Oct 22 2025
Benzinga
BTIG Reaffirms Buy Rating for Arcturus Therapeutics, Reduces Price Target to $23
Oct 22 2025
Benzinga
Guggenheim Lowers Arcturus Therapeutics Rating to Neutral
Oct 22 2025
Benzinga
Zacks.com Spotlights Flux Power, Aura Minerals, Arcturus Therapeutics, and Sterling Infrastructure
Oct 22 2025
NASDAQ.COM
Arcturus Shares Drop 55.79% Following Interim Phase 2 Cystic Fibrosis Results
Oct 22 2025
NASDAQ.COM
What Caused Arcturus Therapeutics Stock (ARCT) to Drop 55% Today?
Oct 22 2025
TipRanks
Show More News